Sana Biotechnology, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
RA Capital Management and its principals have filed a Schedule 13G reporting a 6.3% beneficial ownership stake in Sana Biotechnology, Inc.
NASDAQ
BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Sana Biotechnology Inc., holding 13,643,304 shares of common stock as of December 31, 2025.
NASDAQ
ARCH Venture Funds and affiliated entities report a combined 17.2% beneficial ownership in Sana Biotechnology, Inc., with Robert Nelsen holding 17.3%.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.9% of Sana Biotechnology, Inc.'s common stock as of March 31, 2025.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 4.81% passive beneficial ownership stake in Sana Biotechnology Inc. as of December 31, 2024.